Etanercept exacerbates inflammation and pathology in a rabbit model of active pulmonary tuberculosis.
Treatment of chronic inflammatory diseases with tumor necrosis factor alpha (TNF-α) antagonists has been associated with increased risk of tuberculosis (TB). We examined the usefulness of the rabbit model of active pulmonary TB for studying the impact of the human immune modulatory reagent etanercept on the host immune response. Control of Mycobacterium tuberculosis (Mtb) infection, disease pathology, and the global transcriptional response in Mtb-infected lungs of rabbits were studied. Etanercept treatment exacerbated disease pathology and reduced bacillary control in the lungs, compared with infected untreated animals. Reduced collagen and fibrin deposition in the granulomas was associated with significant downregulation of the collagen metabolism and fibrosis network genes and upregulation of genes in the inflammatory response and cell recruitment networks in the lungs of etanercept treated, compared with untreated rabbits. Our results suggest that targeting the TNF-α signaling pathway disrupts the tissue remodeling process, which is required for the formation and maintenance of well-differentiated granulomas and for control of Mtb growth in the lungs. These results validate the use of the rabbit model for investigating the impact of selected human immune modulatory drugs, such as a TNF-α antagonist, on the host immune response and pathogenesis in TB.
1 Laboratory of Mycobacterial Immunity and Pathogenesis, The Public Health Research Institute (PHRI), Rutgers Biomedical and Health Sciences, Rutgers The State University of New Jersey , Newark, New Jersey.
Liana
L
Tsenova
Paul
P
O'Brien
Jennifer
J
Holloway
Blas
B
Peixoto
Patricia
P
Soteropoulos
Dorothy
D
Fallows
Gilla
G
Kaplan
Selvakumar
S
Subbian
D000818:Animals; D003094:Collagen / Q000276:immunology; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000276:immunology; D000068800:Etanercept / Q000009:adverse effects / Q000276:immunology* / Q000494:pharmacology*; D005337:Fibrin / Q000276:immunology; D006099:Granuloma / Q000276:immunology / Q000382:microbiology; D007249:Inflammation / Q000276:immunology / Q000382:microbiology / Q000473:pathology*; D008168:Lung / Q000276:immunology / Q000382:microbiology; D009169:Mycobacterium tuberculosis / Q000276:immunology; D011817:Rabbits; D014397:Tuberculosis, Pulmonary / Q000276:immunology / Q000382:microbiology / Q000473:pathology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology; D015854:Up-Regulation / Q000276:immunology
D014409:Tumor Necrosis Factor-alpha; D005337:Fibrin; D003094:Collagen; D000068800:Etanercept